CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS
Clene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8 ® in amyotrophic lateral sclerosis (ALS
How this was made
The 30-second read
Why it matters
The NDA filing represents a pivotal regulatory step; the direct offering secures runway through early 2027, both likely to be priced in by the market.
Market read
First‑report 8‑K provides fresh regulatory and financing news, creating immediate trading relevance for CLNN.
What to watch
Potential dilution from future warrant exercises and the modest size of the raise may limit long-term impact.
Clene submitted an NDA seeking accelerated approval for CNM-Au8 in ALS, reported third-quarter net income driven by warrant and derivative liability revaluations, and said cash resources support operations through mid-first quarter 2027.
The NDA submission is a pivotal regulatory milestone and quarterly operating loss narrowed, but the reported $3.9 million net income was driven by $10.3 million of other income, net, including fair-value changes in warrant and derivative liabilities. Cash resources were expected to fund operations only through mid-first quarter 2027.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 product revenueGAAP | $43K | – | – |
| Q3 2026 royalty revenueGAAP | $13K | – | – |
| Q3 2026 total revenueGAAP | $56K | – | – |
| Nine months ended September 30, 2026 product revenueGAAP | $118K | – | – |
| Nine months ended September 30, 2026 royalty revenueGAAP | $43K | – | – |
| Nine months ended September 30, 2026 total revenueGAAP | $161K | – | – |
| Q3 2026 cost of revenueGAAP | $16K | – | – |
| Nine months ended September 30, 2026 cost of revenueGAAP | $52K | – | – |
| Q3 2026 research and development expensesGAAP | $4.45M | – | an increase of approximately 27% |
| Nine months ended September 30, 2026 research and development expensesGAAP | $8.25M | – | – |
| Q3 2026 general and administrative expensesGAAP | $1.94M | – | a decrease of approximately 10% |
| Nine months ended September 30, 2026 general and administrative expensesGAAP | $5.62M | – | – |
| Q3 2026 total operating expensesGAAP | $6.40M | – | – |
| Nine months ended September 30, 2026 total operating expensesGAAP | $13.92M | – | – |
| Q3 2026 loss from operationsGAAP | −$6.35M | – | – |
| Nine months ended September 30, 2026 loss from operationsGAAP | −$13.76M | – | – |
| Q3 2026 interest incomeGAAP | $50K | – | – |
| Q3 2026 interest expenseGAAP | −$665K | – | – |
| Q3 2026 change in fair value of common stock warrant liabilitiesGAAP | $7.49M | – | – |
| Q3 2026 change in fair value of derivative liabilitiesGAAP | $3.37M | – | – |
| Q3 2026 research and development tax credits and unrestricted grantsGAAP | $16K | – | – |
| Q3 2026 total other income (expense), netGAAP | $10.26M | – | – |
| Nine months ended September 30, 2026 total other income (expense), netGAAP | −$3.85M | – | – |
| Q3 2026 net income (loss) before income taxesGAAP | $3.92M | – | – |
| Nine months ended September 30, 2026 net income (loss) before income taxesGAAP | −$17.6M | – | – |
| Q3 2026 income tax expenseGAAP | $ — (in thousands) | – | – |
| Q3 2026 net income (loss)GAAP | $3.92M | – | – |
| Nine months ended September 30, 2026 net income (loss)GAAP | −$17.6M | – | – |
| Q3 2026 basic net income (loss) per shareGAAP | $ 0.30 | – | – |
| Q3 2026 diluted net income (loss) per shareGAAP | $ 0.05 | – | – |
| Nine months ended September 30, 2026 basic net income (loss) per shareGAAP | $ (1.42) | – | – |
| Nine months ended September 30, 2026 diluted net income (loss) per shareGAAP | $ (1.42) | – | – |
| Q3 2026 weighted average common shares used to compute basic net income (loss) per shareGAAP | 13,079,599 | – | – |
| Q3 2026 weighted average common shares used to compute diluted net income (loss) per shareGAAP | 14,668,742 | – | – |
| Nine months ended September 30, 2026 weighted average common shares used to compute basic net income (loss) per shareGAAP | 12,374,096 | – | – |
| Nine months ended September 30, 2026 weighted average common shares used to compute diluted net income (loss) per shareGAAP | 12,374,096 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Product revenue, Q3 2026Not stated | $43K | – | – |
| Royalty revenue, Q3 2026Not stated | $13K | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Through mid-first quarter 2027 outlook
- NoteThe Company expects the proceeds from the $4.0 million registered direct offering to fund operations through mid-first quarter 2027.
- NoteClene plans to randomize the first participants for the Phase 3 RESTORE-ALS trial in the second quarter of 2027.
- NoteSubject to FDA acceptance of the NDA for review, the Company could receive $6.7 million to $7.8 million in proceeds from common stock warrants issued in its January 2026 financing.
What drove it
- Clene submitted an NDA to the FDA in October seeking accelerated approval of CNM-Au8 for ALS.
- The NDA is supported by NfL biomarker and clinical data from the Phase 2 HEALEY ALS Platform Trial and its open-label extension, the Phase 2 RESCUE-ALS Trial, and the NIH-sponsored Expanded Access Protocol for CNM-Au8.
- Q3 research and development expense increased primarily due to higher regulatory expenses for the NDA submission, higher manufacturing expense, and higher personnel expense.
- The research and development increase was partially offset by lower clinical expenses related to CNM-Au8 in ALS and MS, lower stock-based compensation expense, and lower grant revenue recorded as a reduction to research and development expense.
- General and administrative expense declined primarily due to lower insurance costs, legal fees, finance and accounting fees, and stock-based compensation expense.
- The shift to total other income, net, from total other expense, net, was primarily due to changes in the fair value of common stock warrant liabilities and derivative liabilities.
Concerns
- Clene expects its resources as of September 30, 2026 to provide operating runway only through mid-first quarter 2027.
- The $6.7 million to $7.8 million of potential warrant proceeds is subject to FDA acceptance of the NDA for review.
- Q3 operating loss was $ (6,347) (in thousands), while reported net income included $ 7,493 (in thousands) from the change in fair value of common stock warrant liabilities and $ 3,368 (in thousands) from the change in fair value of derivative liabilities.
- The Company reported total stockholders’ deficit of $ (14,808) (in thousands) at September 30, 2026.
- The confirmatory Phase 3 RESTORE-ALS trial is planned to initiate in the second quarter of 2027.
What to watch
- FDA acceptance and review of the CNM-Au8 NDA seeking accelerated approval for ALS.
- Potential receipt of $6.7 million to $7.8 million from the exercise of warrants issued in the January 2026 financing.
- Timing of first participant randomization in the Phase 3 RESTORE-ALS trial in the second quarter of 2027.
- Operating runway through mid-first quarter 2027 and the Company’s ability to obtain additional funding for operations.
Balance sheet and cash flow
- Cash and cash equivalents totaled $9.9 million as of September 30, 2026, compared to $5.2 million as of December 31, 2025.
- Net cash used in operating activities was $11.7 million for the nine months ended September 30, 2026, compared to $13.7 million for the same period in 2025.
- Cash and cash equivalents were $ 9,887 (in thousands) at September 30, 2026, compared with $ 5,189 (in thousands) at December 31, 2025.
- Notes payable, current portion was $ 4,974 (in thousands) and convertible notes payable, current portion was $ 7,980 (in thousands) at September 30, 2026.
- Notes payable, net of current portion was $ 964 (in thousands) and convertible notes payable, net of current portion was $ 5,295 (in thousands) at September 30, 2026.
- Total current liabilities were $ 17,114 (in thousands), total liabilities were $ 36,965 (in thousands), and total stockholders’ deficit was $ (14,808) (in thousands) at September 30, 2026.
- In September, the Company closed a $4.0 million registered direct offering of common stock priced at $3.28 per share.
Analysis
Clene’s central third-quarter development was its October NDA submission seeking accelerated approval of CNM-Au8 in ALS. The company said the submission is supported by NfL biomarker and clinical data from the Phase 2 HEALEY ALS Platform Trial and its open-label extension, the Phase 2 RESCUE-ALS Trial, and the NIH-sponsored Expanded Access Protocol. Clene also plans to randomize the first participants in the Phase 3 RESTORE-ALS confirmatory trial during the second quarter of 2027, with survival as the primary endpoint and time to ALS clinical worsening events as the secondary efficacy endpoint.
Revenue remained very small in absolute terms, with Q3 total revenue of $ 56 (in thousands), compared with $ 15 (in thousands) in the prior-year quarter. Product revenue was $ 43 (in thousands), while royalty revenue was $ 13 (in thousands). For the nine months ended September 30, 2026, total revenue was $ 161 (in thousands), compared with $ 123 (in thousands) in the same period of 2025. The filing did not provide an operational explanation for product or royalty revenue movement.
Operating spending increased year over year in the quarter. Research and development expense was $ 4,447 (in thousands), an increase of approximately 27%, driven primarily by NDA regulatory work as well as higher manufacturing and personnel expenses. General and administrative expense declined to $ 1,940 (in thousands) from $ 2,150 (in thousands), primarily reflecting lower insurance, legal, finance and accounting, and stock-based compensation costs. Total operating expenses were $ 6,403 (in thousands), and loss from operations was $ (6,347) (in thousands).
The quarter’s $ 3,915 (in thousands) of GAAP net income did not result from operating profitability. Total other income, net, was $ 10,262 (in thousands), including $ 7,493 (in thousands) from the change in fair value of common stock warrant liabilities and $ 3,368 (in thousands) from the change in fair value of derivative liabilities. For the nine months ended September 30, 2026, Clene reported a net loss of $ (17,600) (in thousands), compared with $ (16,947) (in thousands) in the same period of 2025.
Liquidity remains the immediate financial focus. Cash and cash equivalents were $9.9 million as of September 30, 2026, and net cash used in operating activities was $11.7 million for the first nine months of 2026. A $4.0 million September registered direct offering was expected to fund operations through mid-first quarter 2027. The company also identified $6.7 million to $7.8 million in potential warrant proceeds, contingent on FDA acceptance of the NDA for review. The near-term outlook therefore depends on the NDA process, access to conditional warrant proceeds, and funding availability ahead of the planned Phase 3 trial.
Management, verbatim
Clene’s submission of the NDA for CNM-Au8 is a pivotal achievement for the company and, more importantly, a meaningful step toward bringing new treatment options to people living with ALS.
Rob Etherington, President and CEO of Clene
Not in the filing
stated, not guessed- Gross margin and gross profit
- Non-GAAP financial measures, including non-GAAP operating income, net income, and EPS
- Prior-quarter financial comparisons
- Quarterly operating cash flow and free cash flow
- Financial revenue, gross-margin, operating-expense, or tax-rate guidance
- Dividend and share repurchase information
- Prior outlook for comparison
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Clene is a late-stage biopharma developing mitochondrial‑targeted therapies for neurodegenerative diseases.
Ticker impact
Clene Inc. disclosed Q3 2026 results, filed an NDA for CNM-Au8 targeting ALS, and completed a $4.0M direct offering.
potential upside as market prices in accelerated approval prospects and additional liquidity
FDA submission is a material catalyst for a biotech; the raise reduces financing risk, both supporting a bullish short-term move.
Market effects
Advances in ALS therapy may boost sentiment toward neurodegenerative biotech peers.
Limited to US biotech sector; no broader regional effect.
Modest; primarily affects investors focused on US-listed biotech stocks.
Counterpoint
If the FDA delays review or requests additional data, the stock could face pressure despite the cash raise.
Key entities
- CompanyClene Inc.
Nasdaq‑listed biotech developing CNM‑Au8 for ALS.
- RegulatorFDA
U.S. agency reviewing the NDA for accelerated approval.
